Abstract 578P
Background
The risk of second primary cancers is increased after most cancer diagnoses, through various mechanisms including common cancer risk factors and treatments’ carcinogenicity. Post-treatment follow-up visits are relevant teachable moments enabling to advise patients on health promotion, including second cancers prevention. We aimed to describe current practices and perceptions of HHCPs in charge of FU care after curative treatment of a first cancer, regarding the promotion of standard screening and fight against major risk factors for secondary cancers.
Methods
An anonymous online survey comprising 11 questions was sent to around 1,800 French HHCPs practicing in oncology between 27/06 and 7/07/2024. Main objective was a descriptive analysis of practices and perceptions of the importance and feasibility of these preventive approaches. Most questions used Likert scales graded from 0 (never/nil) to 10 (most of the time/very important).
Results
Of the 415 respondents, 53% were medical oncologists, 12% radiotherapy oncologists, 14% surgeons, 8% organ specialists, 2% GPs, 5% nurses, 7% others. They followed pts with various primaries including cancers of the breast (BC) 67%, digestive tract 28%, gynecologic 35%, urologic 27%, lung 19%, head and neck 24%, skin 14%, sarcoma 18%. HHCPs declared promoting screening mammography for non-BC pts with a median [interquartile] score of 8/10 [5-10], FIT test 5/10 [1-7], cervical cancer screening 7/10 [2-9], smoking cessation 9/10 [7-10]; and talking about alcohol 7/10 [5-9]. 75% talked about obesity management if indicated. The median perception of the importance of the role of HHCPs in tertiary cancer prevention was 9/10 [7-10]. The perception of the feasibility of this task was 8/10 [6-10]. The results did not differ significantly between HHCP categories.
Conclusions
The inclusion of a tertiary prevention activity as part of cancer FU care is already partly effective among HHCPs, but could be improved. Overall, it is very favorably perceived by HHCPs. Its generalization, organization and development could have an important health impact, which has yet to be modelled.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Has not received any funding.
Disclosure
L. Veron: Financial Interests, Personal, Advisory Board: Roche. P. Abdayem: Non-Financial Interests, Personal, Other, funding for conference attendance: Pfizer, Lilly; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD. C. Lefeuvre-Plesse: Financial Interests, Personal, Advisory Board: Roche, Pfizer, Daiichi Sankyo, astra zeneka; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Clovis; Financial Interests, Institutional, Local PI: AstraZeneca; Non-Financial Interests, Personal, Member: Societe Française de Senologie et de Pathologie Mammaire; Other, Personal, Other, support financier pour participation à des congrès: Novartis, Roche, Eisai, Pfizer, Pierre Fabre, Daichi Sankyo, AstraZeneca, Amgen, Clovis. I. Vaz Luis: Financial Interests, Institutional, Invited Speaker: Amgen, Pfizer/Edimark, AstraZeneca; Financial Interests, Institutional, Writing Engagement: Pfizer/Edimark; Financial Interests, Institutional, Advisory Board, Consulting/ AB: Novartis; Financial Interests, Institutional, Advisory Board: Sandoz; Financial Interests, Personal, Other, Travelling: Novartis; Financial Interests, Institutional, Other, Research Funding: Resilience; Financial Interests, Institutional, Funding: Resilience; Non-Financial Interests, Personal, Member, Member of WG: ASCO. S. Delaloge: Financial Interests, Institutional, Advisory Board: Novartis, Sanofi, Gilead; Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Institutional, Advisory Board, ad board: Besins Healthcare; Financial Interests, Institutional, Invited Speaker, ESMO symposium: Gilead; Financial Interests, Institutional, Advisory Board, scientific board: Elsan; Financial Interests, Institutional, Steering Committee Member: Roche Genentech, BMS, Sanofi; Non-Financial Interests, Personal, Member of Board of Directors, Société Française de Sénologie et Pathologie Mammaire: SFSPM; Non-Financial Interests, Personal, Principal Investigator, H2020 funding: European Commission. All other authors have declared no conflicts of interest.